solute carrier family 12 member 6Genealiases: ACCPN · CMT2II · KCC3 · KCC3A · KCC3B
Q-omics provides the consensus-scored SLC12A6 profile across patient tissues and cancer cell-line models. SLC12A6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC12A6 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SLC12A6 RNA expression shows 21,171 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where SLC12A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC12A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC12A6 survival associations across molecular data types. SLC12A6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC12A6 RNA expression–survival associations across cancer types. High SLC12A6 expression shows unfavorable associations in THCA, KIRP and UVM, but favorable associations in KIRC, HNSC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC12A6 RNA expression.
This table summarizes SLC12A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC12A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC12A6 shows lower tumor expression in THCA, BRCA, COAD and LUAD and higher tumor expression in CHOL and LIHC. The THCA box plot shows higher SLC12A6 RNA expression in normal versus tumor tissue (log2 FC = −0.742, t-test p < 0.001).
This table shows molecular features associated with SLC12A6 in patient tissues and cancer cell lines. In patient samples, SLC12A6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC12A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
